This article is more than 5 years old. Information may no longer be current.
FDA expands Ibrance approval for metastatic breast cancer
Click Here to Manage Email Alerts
The FDA expanded the approval of palbociclib for the treatment of metastatic breast cancer.
Palbociclib (Ibrance, Pfizer) — a cyclin-dependent kinase 4/6 inhibitor — now is approved for use in combination with fulvestrant for the treatment of women with hormone receptor-positive, HER-2–negative metastatic breast cancer who progressed on endocrine therapy.
The agent already had been approved for use in combination with letrozole as initial endocrine-based therapy in postmenopausal women with HR-positive, HER-2–negative advanced or metastatic breast cancer.
The FDA based the expanded approval on results from the phase 3 PALOMA-3 trial, which included 521 pre-, peri- and postmenopausal women with HR-positive, HER-2–negative metastatic breast cancer whose disease progressed during or after endocrine therapy in the adjuvant or metastatic settings. Researchers assigned women 2:1 to fulvestrant plus palbociclib or fulvestrant plus placebo.
Results showed the addition of palbociclib to fulvestrant prolonged median PFS (9.5 months vs. 4.6 months; HR = 0.46; 95% CI, 0.36-0.59). Researchers also reported a higher overall response rate (24.6% vs. 10.9%) and longer duration of response (9.3 months vs. 7.6 months) in the combination group.
“[This] news gives more women with metastatic breast cancer the opportunity to benefit from this first-in-class medicine,” Liz Barrett, global president and general manager of Pfizer Oncology, said in a press release. “Since Ibrance was approved just over one year ago, physicians across the U.S. have embraced it as a standard of care in the first-line setting. The expanded approval of Ibrance is supported by a robust body of evidence and underscores Pfizer’s continued commitment to addressing the needs of the metastatic breast cancer community.”
In PALOMA-3, the most common any-grade adverse reactions among palbociclib-treated patients included neutropenia (83% in the combination group vs. 4% for fulvestrant alone), leukopenia (53% vs. 5%), infections (47% vs. 31%), fatigue (41% vs. 29%), nausea (34% vs. 28%), anemia (30% vs. 13%), stomatitis (28% vs. 13%), headache (26% vs 20%), diarrhea (24% vs 19%) and thrombocytopenia (23% vs 0%).